Enzyme‐mediated synthesis of Molnupiravir: paving the way for the application of biocatalysis in pharmaceutical industry
- Cruz, Guillermo 1
- Acosta, Javier 1
- Del Arco, Jon 1
- Clemente‐Suarez, Vicente Javier 12
- Deroncele, Víctor 3
- Fernández‐Lucas, Jesús 12
-
1
Universidad Europea de Madrid
info
-
2
Universidad de la Costa
info
- 3 Selabtec Sciences C\ Àlvarez de Castro, 63 08100 Mollet del Vallès Spain
ISSN: 1867-3880, 1867-3899
Datum der Publikation: 2022
Art: Artikel
Andere Publikationen in: ChemCatChem
Zusammenfassung
Molnupiravir (Lagevrio®) is an orally-administered anti-COVID-19 agent. Due to the urgency to meet the worldwide demand and the growing environmental concern, there is a need for speed in the industrial implementation of novel and efficient bioprocesses for Molnupiravir synthesis. This concept paper aims to review the most relevant milestones that have guided important developments in the enzyme-mediated synthesis of Molnupiravir, including detailed comments on the advantages and drawbacks of the different synthetic routes. Finally, based on a personal perspective, new greener processes for Molnupiravir manufacturing are proposed and discussed.
Informationen zur Finanzierung
Geldgeber
-
Ministerio de Ciencia e Innovación
- PID2020-117025RB−I00
Bibliographische Referenzen
- 10.1038/nrd4010
- 10.1021/cr900028p
- 10.1002/asia.201900841
- Cox R. M., (2021), Nat. Microbiol., 6, pp. 1, 10.1038/s41564-020-00847-y
- 10.1002/9783527812103
- 10.2174/138527208783743723
- 10.1016/j.molcatb.2016.08.015
- 10.1007/s00253-015-6642-x
- Del Arco J., (2017), Curr. Pharm. Des., 23, pp. 6898
- Kaspar F., (2020), Green Chem., 23, pp. 37, 10.1039/D0GC02665D
- 10.1007/s00253-018-9242-8
- 10.1038/s41564-020-00835-2
- 10.1038/s41594-021-00651-0
- 10.1016/j.jbc.2021.100867
- Syed Y. Y., (2022), Drugs, 82, pp. 455, 10.1007/s40265-022-01684-5
- Whitley R., (2022), N. Engl. J. Med., 386, pp. 592, 10.1056/NEJMe2117814
- G. R. Painter G. R. Bluemling M. G. Natchus D. Guthrie WO2019113462 A1 2019;
- G. R. Painter D. Perryman G. R. Bluemling WO2019173602 2019.
- 10.1002/ejoc.202001340
- Hu T., (2022), Org. Process Res. Dev., 2, pp. 358, 10.1021/acs.oprd.1c00419
- 10.1039/D0CC05944G
- 10.1055/a-1275-2848
- 10.1021/acsomega.1c00772
- 10.1021/acs.oprd.1c00033
- 10.1021/acscentsci.1c00608
- Jhulki I., (2021), ACS Cent. Sci., 7, pp. 1963, 10.1021/acscentsci.1c01356
- Simić S., (2021), Chem. Rev., 122, pp. 1052, 10.1021/acs.chemrev.1c00574
- 10.1186/1860-5397-2-3
- 10.1021/jacs.1c11048
- Mullin R., (2021), C&EN Global Enterprise, 99, pp. 19, 10.1021/cen-09906-buscon14
- 10.1016/j.jbiosc.2017.01.005
- 10.1016/j.jbiosc.2017.07.016
- 10.2174/138527206777697995
- Acosta J., (2020), Front. Bioeng. Biotechnol., 8, pp. 593, 10.3389/fbioe.2020.00593
- 10.1002/cbic.201900397
- 10.1128/AEM.07605-11
- 10.1016/j.foodchem.2017.05.136
- 10.1016/j.biortech.2020.124547
- 10.1016/j.biortech.2021.125649
- 10.3390/catal9040355
- 10.1002/cpz1.347
- 10.1016/j.jbiotec.2010.11.013
- 10.1016/j.ijbiomac.2021.09.164
- 10.1002/cbic.202000679
- 10.1016/j.bbapap.2019.140304
- 10.1016/j.biortech.2020.123258
- Rivero C. W., (2021), Biomol. Eng., 11, pp. 657
- 10.1002/adsc.200404019